IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: In Figure 11B, it is evident that the CML + rHDL-(1:1) group demonstrated the least-IL-6-stained area (2.6%), which is 5.3-fold (p < 0.01) lower than the IL-6-stained area noticed in CML + PBS group, underscoring the potent anti-inflammatory activity associated with concurrent presence of CIGB-258.